VYOME HOLDINGS, INC. Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill)
VYOME HOLDINGS, INC. (HIND) reported Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill) of $777.00 thousand for the 12-month period ending 2023-12-31, per its 10-K filed 2024-04-01.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill · last filed 2024-11-14
- VYOME HOLDINGS, INC. impairment of intangible assets, indefinite-lived (excluding goodwill) for the quarter ending 2023-12-31 was $0.00, a 100.00% decline year-over-year.
- VYOME HOLDINGS, INC. impairment of intangible assets, indefinite-lived (excluding goodwill) for the quarter ending 2023-09-30 was $777.00K, a 88.82% decline year-over-year.
- VYOME HOLDINGS, INC. impairment of intangible assets, indefinite-lived (excluding goodwill) for the quarter ending 2022-12-31 was $11.80M.
- VYOME HOLDINGS, INC. impairment of intangible assets, indefinite-lived (excluding goodwill) for the quarter ending 2022-09-30 was $6.95M.
- VYOME HOLDINGS, INC. impairment of intangible assets, indefinite-lived (excluding goodwill) for fiscal 2023 was $777.00K, a 95.85% decline from fiscal 2022.
- VYOME HOLDINGS, INC. impairment of intangible assets, indefinite-lived (excluding goodwill) for fiscal 2022 was $18.74M, a 38.84% decline from fiscal 2021.
- VYOME HOLDINGS, INC. impairment of intangible assets, indefinite-lived (excluding goodwill) for fiscal 2021 was $30.65M.
- VYOME HOLDINGS, INC. impairment of intangible assets, indefinite-lived (excluding goodwill) for fiscal 2020 was $0.00.
| Period end | Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill) 3 month | Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill) 6 month | Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill) 9 month | Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill) 12 month |
|---|---|---|---|---|
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-04-01 | $777.00K derived: sum of 2 quarters · filed 2024-11-14 | $777.00K 10-K · filed 2024-04-01 | |
| 2023-09-30 | $777.00K 10-Q · filed 2024-11-14 | $777.00K 10-Q · filed 2024-11-14 | ||
| 2022-12-31 | $11.80M derived: 10-K 12 month − 10-Q 9 month · filed 2024-04-01 | $18.74M derived: sum of 2 quarters · filed 2024-04-01 | $18.74M 10-K · filed 2024-04-01 | |
| 2022-09-30 | $6.95M 10-Q · filed 2022-11-14 | $6.95M 10-Q · filed 2022-11-14 | ||
| 2021-12-31 | $30.65M 10-K · filed 2023-04-17 | |||
| 2020-12-31 | $0.00 10-K · filed 2022-04-08 | |||
| 2020-06-30 | $0.00 10-K · filed 2022-04-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Tvardi Therapeutics, Inc. (TVRD) | United States | $0.014B | |
| BullFrog AI Holdings, Inc. (BFRG) | United States | $0.014B | |
| ACTUATE THERAPEUTICS, INC. (ACTU) | United States | $0.015B | |
| Anebulo Pharmaceuticals, Inc. (ANEB) | United States | $0.015B | |
| LISATA THERAPEUTICS, INC. (LSTA) | United States | $0.014B | -2.13 |
| Lantern Pharma Inc. (LTRN) | United States | $0.015B | -2.87 |
| Vistagen Therapeutics, Inc. (VTGN) | United States | $0.013B | -0.14 |
| MUSTANG BIO, INC. (MBIO) | United States | $0.013B | |
| Citius Pharmaceuticals, Inc. (CTXR) | United States | $0.016B | -133.06 |
| AEON Biopharma, Inc. (AEON) | United States | $0.013B | -0.36 |